邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

蕈样肉芽肿免疫标志物及相关药物治疗进展

韩婕,  余红

downloadPDF
文章导航 > 协和医学杂志  > 2021 >  12(4): 568-574
韩婕, 余红. 蕈样肉芽肿免疫标志物及相关药物治疗进展[J]. 协和医学杂志, 2021, 12(4): 568-574. doi: 10.12290/xhyxzz.20200278
引用本文: 韩婕, 余红. 蕈样肉芽肿免疫标志物及相关药物治疗进展[J]. 协和医学杂志, 2021, 12(4): 568-574. doi: 10.12290/xhyxzz.20200278
shu
HAN Jie, YU Hong. Progress in Immune Markers and Relevant Drug Therapies of Mycosis Fungoides[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 568-574. doi: 10.12290/xhyxzz.20200278
Citation: HAN Jie, YU Hong. Progress in Immune Markers and Relevant Drug Therapies of Mycosis Fungoides[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 568-574. doi: 10.12290/xhyxzz.20200278
shu

蕈样肉芽肿免疫标志物及相关药物治疗进展

doi: 10.12290/xhyxzz.20200278

  • 上海交通大学医学院附属新华医院皮肤科，上海 200092

详细信息
    通讯作者:

    余红  电话：021-25076929，E-mail：smallgrass6@163.com

  • 中图分类号: R739.5;R730.5

Progress in Immune Markers and Relevant Drug Therapies of Mycosis Fungoides

  • Department of Dermatology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

More Information

    摘要
  • 摘要: 蕈样肉芽肿(mycosis fungoides，MF)是一种原发性皮肤T细胞淋巴瘤，既往研究证实其发病与免疫学异常密切相关。近年来，治疗MF的新药陆续出现，尤其是分子靶向药物，其作用机制与相应的免疫标志物相关。本文就MF免疫标志物及其相关药物治疗进展进行综述。
    Abstract: Mycosis fungoides (MF) is a primary cutaneous T-cell lymphoma. The pathogenesis is closely associated with immunological abnormalities. Some novel drugs have emerged recently, especially molecular targeted drugs, which are related to the immune markers of MF. Here we summarized the progress of its immune markers and related drug therapies.
    作者贡献：韩婕负责查阅文献、撰写论文；余红负责审阅、修订论文。
    利益冲突：无
    • HTML全文
    • 参考文献(52)
  • [1] 贾近博, 张乔安, 陈明华. 趋化因子受体4与Foxp3+调节性T细胞在蕈样肉芽肿皮损中的表达及其意义初探[J]. 临床皮肤科杂志, 2014, 43: 389-392. https://www.cnki.com.cn/Article/CJFDTOTAL-LCPF201407002.htm

    Jia JB, Zhang QA, Chen MH. The expression and significance of CC chemokine receptor 4 and Foxp3+ regulatory T cells in mycosis fungoides[J]. Linchuang Pifuke Zazhi, 2014, 43: 389-392. https://www.cnki.com.cn/Article/CJFDTOTAL-LCPF201407002.htm
    [2] Hsi AC, Lee SJ, Rosman IS, et al. Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implications[J]. J Am Acad Dermatol, 2015, 72: 159-167. doi:  10.1016/j.jaad.2014.09.022
    [3] Hodak E, Amitay-Laish I. Mycosis fungoides: A great imitator[J]. Clin Dermatol, 2019, 37: 255-267. doi:  10.1016/j.clindermatol.2019.01.004
    [4] Kalay Yildizhan I, Sanli H, Akay BN, et al. CD8+cytotoxic mycosis fungoides: a retrospective analysis of clinical features and follow-up results of 29 patients[J]. Int J Dermatol, 2020, 59: 127-133. doi:  10.1111/ijd.14689
    [5] Martinez-Escala ME, Kantor RW, Cices A, et al. CD8+ mycosis fungoides: A low-grade lymphoproliferative disorder[J]. J Am Acad Dermatol, 2017, 77: 489-496. doi:  10.1016/j.jaad.2017.05.015
    [6] Kampa F, Mitteldorf C. A review of CD30 expression in cutaneous neoplasms[J]. J Cutan Pathol, 2021, 48: 495-510. doi:  10.1111/cup.13894
    [7] Danish HH, Liu S, Jhaveri J, et al. Validation of cutane-ous lymphoma international prognostic index(CLIPI) for mycosis fungoides and Sézary syndrome[J]. Leuk Lymphoma, 2016, 57: 2813-2819. doi:  10.3109/10428194.2016.1173210
    [8] Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1, 263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009[J]. Clin Cancer Res, 2012, 18: 5051-5060. doi:  10.1158/1078-0432.CCR-12-0604
    [9] Sugaya M, Morimura S, Suga H, et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis[J]. J Dermatol, 2015, 42: 613-615. doi:  10.1111/1346-8138.12852
    [10] Shono Y, Suga H, Kamijo H, et al. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome[J]. Acta Derm Venereol, 2019, 99: 809-812. doi:  10.2340/00015555-3207
    [11] Maj J, Jankowska-Konsur AM, Hałoń A, et al. Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides[J]. Postepy Dermatol Alergol, 2015, 32: 437-442. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697019/
    [12] Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides[J]. J Am Acad Dermatol, 2003, 48: 23-30. doi:  10.1067/mjd.2003.132
    [13] Rubio Gonzalez B, Zain J, Rosen ST, et al. Tumor microenvironment in mycosis fungoides and Sézary syndrome[J]. Curr Opin Oncol, 2016, 28: 88-96. doi:  10.1097/CCO.0000000000000243
    [14] Li X, Sun S, Li N, et al. High Expression of CCR7 Predicts Lymph Node Metastasis and Good Prognosis in Triple Negative Breast Cancer[J]. Cell Physiol Biochem, 2017, 43: 531-539. doi:  10.1159/000480526
    [15] Hu SC, Lin CL, Hong CH, et al. CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation[J]. J Dermatol Sci, 2014, 74: 31-38. doi:  10.1016/j.jdermsci.2013.12.003
    [16] Hong CH, Lin SH, Lee CH. CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma[J]. In Vivo, 2019, 33: 793-800. doi:  10.21873/invivo.11541
    [17] Pileri A, Agostinelli C, Sessa M, et al. Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease[J]. Virchows Arch, 2017, 470: 575-582. doi:  10.1007/s00428-017-2107-1
    [18] Fawzy MM, El-Latif MIA, Hegazy RA, et al. Expression of langerhans cells, dermal dendritic cells and plasmacytoid dendritic cells in early stage mycosis fungoides: Case control study[J]. J Dermatol Sci, 2016, 84: e24.
    [19] Vieyra-Garcia P, Crouch JD, O'Malley JT, et al. Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma[J]. JCI Insight, 2019, 4: e124233. doi:  10.1172/jci.insight.124233
    [20] Ohmatsu H, Humme D, Gonzalez J, et al. IL-32 induces indoleamine 2, 3-dioxygenase+CD1c+ dendritic cells and indoleamine 2, 3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression[J]. Oncoimmunology, 2016, 6: e1181237. http://europepmc.org/abstract/MED/28344860
    [21] Ohmatsu H, Humme D, Gulati N, et al. IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization[J]. Cancer Immunol Res, 2014, 2: 890-900. doi:  10.1158/2326-6066.CIR-13-0199-T
    [22] Kado JA, Shango M, Mehregan C, et al. Mapping Toll-like receptor activity in different stages of cutaneous T-cell lymphoma[J]. Am J Dermatopathol, 2012, 34: 691-698. doi:  10.1097/DAD.0b013e3182448f7c
    [23] El Tawdy AM, Amin IM, Abdel Hay RM, et al. Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study[J]. Clin Exp Dermatol, 2017, 42: 172-177. doi:  10.1111/ced.13008
    [24] Nguyen GH, Olson LC, Magro CM. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sézary's syndrome[J]. Ann Diagn Pathol, 2017, 28: 54-59. doi:  10.1016/j.anndiagpath.2017.02.003
    [25] Kantekure K, Yang Y, Raghunath P, et al. Expression Patterns of the Immunosuppressive Proteins PD-1/CD279 and PD-L1/CD274 at Different Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides[J]. Am J Dermatopathol, 2012, 34: 126-128. doi:  10.1097/DAD.0b013e31821c35cb
    [26] Zic JA. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome[J]. Dermatol Clin, 2015, 33: 765-776. doi:  10.1016/j.det.2015.05.011
    [27] Janiga J, Kentley J, Nabhan C, et al. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome[J]. Leuk Lymphoma, 2018, 59: 562-577. doi:  10.1080/10428194.2017.1347650
    [28] Stewart JR, Desai N, Rizvi S, et al. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review[J]. Eur J Dermatol, 2018, 28: 764-774. http://www.ncbi.nlm.nih.gov/pubmed/30591425
    [29] Kim YH, Tavallaee M, Sundram U, et al. Phase Ⅱ Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project[J]. J Clin Oncol, 2015, 33: 3750-3758. doi:  10.1200/JCO.2014.60.3969
    [30] Duvic M, Tetzlaff MT, Gangar P, et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis[J]. J Clin Oncol, 2015, 33: 3759-3765. doi:  10.1200/JCO.2014.60.3787
    [31] Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial[J]. Lancet, 2017, 390: 555-566. doi:  10.1016/S0140-6736(17)31266-7
    [32] Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma[J]. Blood, 2015, 125: 1883-1889. doi:  10.1182/blood-2014-09-600924
    [33] Kasamon YL, Chen H, De Claro RA, et al. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome[J]. Clin Cancer Res, 2019, 25: 7275-7280. doi:  10.1158/1078-0432.CCR-19-2030
    [34] Duvic M, Sherman ML, Wood GS, et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides[J]. J Am Acad Dermatol, 2006, 55: 807-813. doi:  10.1016/j.jaad.2006.06.038
    [35] Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies[J]. Clin Lymphoma Myeloma Leuk, 2013, 13: 377-384. doi:  10.1016/j.clml.2013.02.020
    [36] Ohmachi K, Ando K, Ogura M, et al. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study[J]. Cancer Sci, 2018, 109: 794-802. doi:  10.1111/cas.13513
    [37] Kawai H, Ando K, Maruyama D, et al. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma[J]. Cancer Sci, 2021, 112: 2426-2435. doi:  10.1111/cas.14906
    [38] Ramelyte E, Dummer R, Guenova E. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update[J]. Expert Opin Investig Drugs, 2019, 28: 799-809. doi:  10.1080/13543784.2019.1654995
    [39] Shalabi D, Bistline A, Alpdogan O, et al. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS)[J]. Chin Clin Oncol, 2019, 8: 11. doi:  10.21037/cco.2019.01.01
    [40] Lewis DJ, Byekova YA, Emge DA, et al. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series[J]. J Dermatolog Treat, 2017, 28: 567-569. doi:  10.1080/09546634.2017.1294728
    [41] Rook AH, Gelfand JM, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma[J]. Blood, 2015, 126: 1452-1461. http://smartsearch.nstl.gov.cn/paper_detail.html?id=2cefd2fbefc79ce641c0b56665910788
    [42] Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study[J]. J Clin Oncol, 2016, 34: 2698-2704. doi:  10.1200/JCO.2015.65.9789
    [43] Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizu-mab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase Ⅱ Study[J]. J Clin Oncol, 2020, 38: 20-28. http://www.researchgate.net/publication/335905923_Pembrolizumab_in_Relapsed_and_Refractory_Mycosis_Fungoides_and_Sezary_Syndrome_A_Multicenter_Phase_II_Study
    [44] Trager MH, Geskin LJ. Current status of histone deacety-lase inhibitors in cutaneous T-cell lymphoma[J]. G Ital Dermatol Venereol, 2019, 154: 681-95. http://www.ncbi.nlm.nih.gov/pubmed/31859467
    [45] Foss F, Advani R, Duvic M, et al. A Phase Ⅱ trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma[J]. Br J Haematol, 2015, 168: 811-819. doi:  10.1111/bjh.13222
    [46] Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase Ⅱ trial[J]. Eur J Cancer, 2013, 49: 386-394. doi:  10.1016/j.ejca.2012.08.017
    [47] Child F, Ortiz-Romero PL, Alvarez R, et al. Phase Ⅱ multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome[J]. Br J Dermatol, 2016, 175: 80-88. doi:  10.1111/bjd.14427
    [48] Che Y, Ding X, Song J, et al. Effective remission of chidamide on treatment of advanced mycosis fungoides: An unusual case report[J]. Dermatol Ther, 2019, 32: e12944. http://www.ncbi.nlm.nih.gov/pubmed/31012254
    [49] Oka S, Yokote T, Hara S, et al. Effective treatment of a case of refractory mycosis fungoides with imatinib[J]. Br J Haematol, 2006, 133: 353. doi:  10.1111/j.1365-2141.2006.06046.x
    [50] Geskin LJ, Viragova S, Stolz DB, et al. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation[J]. Blood, 2015, 125: 2798-2805. doi:  10.1182/blood-2014-07-590398
    [51] Miyashiro D, Vivarelli AG, Gonçalves F, et al. Progres-sion of mycosis fungoides after treatment with dupilumab: A case report[J]. Dermatol Ther, 2020, 33: e13880. doi:  10.1111/dth.13880
    [52] Ayasse M, Nelson K, Glass F, et al. Mycosis Fungoides Unmasked by Dupilumab Treatment in a Patient With a History of Atopic Dermatitis[J]. Dermatitis, 2020. doi: 10.1097/DER.0000000000000679.[Epubaheadofprint].
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  635
  • HTML全文浏览量:  138
  • PDF下载量:  103
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-11-24
  • 录用日期:  2021-04-08
  • 网络出版日期:  2021-06-28
  • 刊出日期:  2021-07-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！